Abstract
Purpose
The purpose of this study was to investigate the prevalence of prescribed combinations of interacting drugs in the Swedish population.
Methods
This study design was retrospective and cross-sectional, based on a national register of dispensed prescription drugs during the period from January 1 to April 30, 2010. Prescription data was linked to the drug-drug interaction database SFINX to yield the prevalence of interacting combinations dispensed in the population. The study focused in particular on C- (clinically relevant interactions that can be handled, e.g. by dose adjustments), and D-interactions (clinically relevant interactions that should be avoided).
Results
Thirty-eight and 3.8 % of the population were dispensed combinations of drugs classified as C- or D- interactions, respectively, i.e. clinically relevant, involving all therapeutic areas. Half of the D-interactions were associated with increased risk of adverse drug reactions whereas the other half were considered interactions with a potential to cause therapeutic failure. We identified a top 15 list of D-interactions that included 80 % of the total number of interacting drug combinations. Regarding individual drugs, a group of only ten drugs was involved in as much as 94 % of all D-interactions.
Conclusions
This study reveals that the majority of prescribed interacting drug combinations in Sweden involve a limited number of drugs. The findings may increase the awareness among prescribers of these most common drug interactions in clinical practice and highlight an area for pharmacological education. It may also serve as an inventory of potential interactions within different therapeutic areas for further research.
Similar content being viewed by others
References
Bates DW, Spell N, Cullen DJ, Burdick E, Laird N et al (1997) The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. Jama 277:307–311
Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama 279:1200–1205
Mjorndal T, Boman MD, Hagg S, Backstrom M, Wiholm BE et al (2002) Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 11:65–72
Bergman U, Boman G, Wiholm BE (1978) Epidemiology of adverse drug reactions to phenformin and metformin. Br Med J 2:464–466
Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. Jama 289:1652–1658
Pirmohamed M, James S, Meakin S, Green C, Scott AK et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15–19
Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG et al (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16:641–651
Hovstadius B, Hovstadius K, Astrand B, Petersson G (2010) Increasing polypharmacy—an individual-based study of the Swedish population 2005–2008. BMC Clin Pharmacol 10:16
Becker ML, Visser LE, van Gelder T, Hofman A, Stricker BH (2008) Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged > or = 55 years. Drugs Aging 25:145–152
Merlo J, Liedholm H, Lindblad U, Bjorck-Linne A, Falt J et al (2001) Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ 323:427–428
Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21:153–158
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P et al (2007) The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726–735
Bottiger Y, Laine K, Andersson ML, Korhonen T, Molin B et al (2009) SFINX—a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 65:627–633
Marie Eliasson (2011) Project leader PASCAL. Personal communication, October, 2011
Sjöqvist F (1997) A new classification system for drug interactions. Eur J Clin Pharmaco 52(Supp):327a
Statistiska Centralbyrån (SCB), Statistics Sweden, available from: http://www.scb.se/Pages/List____250612.aspx. Accessed November 2013.
Mannheimer B, Eliasson E (2010) Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice. J Intern Med 268:540–548
Reis AM, Cassiani SH (2011) Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo) 66:9–15
Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V (2005) Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther 30:13–20
Vonbach P, Dubied A, Beer JH, Krahenbuhl S (2007) Recognition and management of potential drug-drug interactions in patients on internal medicine wards. Eur J Clin Pharmacol 63:1075–1083
Pasina L, Djade CD, Nobili A, Tettamanti M, Franchi C et al (2013) Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf 22:1054–1060
Egger T, Dormann H, Ahne G, Runge U, Neubert A et al (2003) Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 20:769–776
Mannheimer B, Wettermark B, Lundberg M, Pettersson H, von Bahr C et al (2010) Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. Br J Clin Pharmacol 69:411–417
Settergren J, Eiermann B, Mannheimer B (2013) Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy—a nationwide register study. PLoS One 8:e69545
Immonen S, Valvanne J, Pitkala KH (2013) The prevalence of potential alcohol-drug interactions in older adults. Scand J Prim Health Care 31:73–78
Andersson ML, Bottiger Y, Lindh JD, Wettermark B, Eiermann B (2013) Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care. Eur J Clin Pharmacol 69:565–571
Launiainen T, Sajantila A, Rasanen I, Vuori E, Ojanpera I (2010) Adverse interaction of warfarin and paracetamol: evidence from a post-mortem study. Eur J Clin Pharmacol 66:97–103
Launiainen T, Vuori E, Ojanpera I (2009) Prevalence of adverse drug combinations in a large post-mortem toxicology database. Int J Legal Med 123:109–115
Hosia-Randell HM, Muurinen SM, Pitkala KH (2008) Exposure to potentially inappropriate drugs and drug-drug interactions in elderly nursing home residents in Helsinki, Finland: a cross-sectional study. Drugs Aging 25:683–692
Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C et al (1989) Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 33:1901–1907
Grasela TH Jr, Schentag JJ, Sedman AJ, Wilton JH, Thomas DJ et al (1989) Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother 33:615–617
Janknegt R (1990) Drug interactions with quinolones. J Antimicrob Chemother 26(D):7–29
Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ (1986) Ciprofloxacin and antacids. Lancet 2:48
Sindrup SH, Brosen K, Bjerring P, Arendt-Nielsen L, Larsen U et al (1990) Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 48:686–693
Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH (1996) The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60:636–644
Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K et al (1996) Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51:289–295
Desmeules J, Gascon MP, Dayer P, Magistris M (1991) Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 41:23–26
Laine K, Tybring G, Hartter S, Andersson K, Svensson JO et al (2001) Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 70:327–335
Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44:349–355
Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365:2002–2012
Gasse C, Hollowell J, Meier CR, Haefeli WE (2005) Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 94:537–543
Jonsson AK, Spigset O, Jacobsson I, Hagg S (2007) Cerebral haemorrhage induced by warfarin—the influence of drug-drug interactions. Pharmacoepidemiol Drug Saf 16:309–315
Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30:911–918
Lau HS, de Boer A, Beuning KS, Porsius A (1997) Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 50:619–625
Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J (2006) Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 4:2508–2509
Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG et al (2008) Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48:475–484
Sibbing D, Morath T, Stegherr J, Braun S, Vogt W et al (2009) Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101:714–719
Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G et al (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157(148):e141–145
Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC et al (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Cmaj 180:713–718
Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA et al (2010) Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 30:787–796
Kwok CS, Jeevanantham V, Dawn B, Loke YK (2013) No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol 167:965–974
Gerson LB, McMahon D, Olkin I, Stave C, Rockson SG (2012) Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature. Dig Dis Sci 57:1304–1313
Acknowledgments
We thank Bengt Sjöborg for highly valuable assistance in computerized processing of the Prescribed Drug Register and the SFINX database. We also thank Ylva Böttiger and Lars L Gustafsson for valuable discussions. The study was supported by the Karolinska Institutet, the Swedish Foundation for Clinical Pharmacology and Pharmacotherapy and the Swedish Society for Medical Research.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Holm, J., Eiermann, B., Eliasson, E. et al. A limited number of prescribed drugs account for the great majority of drug-drug interactions. Eur J Clin Pharmacol 70, 1375–1383 (2014). https://doi.org/10.1007/s00228-014-1745-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-014-1745-3